NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RYTM

Rhythm Pharmaceuticals Inc

Jul 03 • 04:00PM ET

65.77

Dollar change -1.15
Percentage change -1.72	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE VRTX MRK NVO SNY LLY TAK VTRS XENE NBIX

| Held by: VTI IWM VXF XBI IWO IBB SCHA VTWO VHT ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.82	Insider Own	8.53%	Shs Outstand	63.49M	Perf Week	7.04%
Market Cap	4.18B	Forward P/E	-	EPS next Y	-1.38	Insider Trans	-5.44%	Shs Float	58.20M	Perf Month	0.15%
Enterprise Value	4.13B	PEG	-	EPS next Q	-0.64	Inst Own	95.47%	Short Float	8.17%	Perf Quarter	26.58%
Income	-173.99M	P/S	30.57	EPS this Y	37.85%	Inst Trans	0.04%	Short Ratio	6.43	Perf Half Y	16.74%
Sales	136.86M	P/B	220.41	EPS next Y	48.72%	ROA	-52.28%	Short Interest	4.76M	Perf YTD	17.49%
Book/sh	0.30	P/C	13.31	EPS next 5Y	-	ROE	-418.97%	52W High	69.89 -5.89%	Perf Year	54.14%
Cash/sh	4.94	P/FCF	-	EPS past 3/5Y	-45.66% -2.34%	ROIC	-63.30%	52W Low	40.46 62.56%	Perf 3Y	1415.44%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	245.54% -	Gross Margin	89.12%	Volatility	3.72% 3.60%	Perf 5Y	185.96%
Dividend TTM	-	EV/Sales	30.16	EPS Y/Y TTM	39.30%	Oper. Margin	-126.13%	ATR (14)	2.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.13	Sales Y/Y TTM	48.88%	Profit Margin	-127.12%	RSI (14)	57.58	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.30	EPS Q/Q	65.72%	SMA20	2.72%	Beta	2.36	Target Price	83.42
Payout	-	Debt/Eq	13.60	Sales Q/Q	25.94%	SMA50	4.72%	Rel Volume	0.85	Prev Close	66.92
Employees	283	LT Debt/Eq	13.50	Earnings	May 07 BMO	SMA200	15.07%	Avg Volume	739.33K	Price	65.77
IPO	Oct 05, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.68% -18.57%	Trades		Volume	628,374	Change	-1.72%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-07-25	Upgrade	BofA Securities	Neutral → Buy	$63
Mar-05-25	Resumed	Stifel	Buy	$78
Jan-02-25	Initiated	Jefferies	Buy	$80
Dec-20-24	Initiated	Oppenheimer	Outperform	$76
Oct-21-24	Initiated	Guggenheim	Buy	$70
Sep-18-24	Initiated	H.C. Wainwright	Buy	$64
Sep-17-24	Initiated	JMP Securities	Mkt Outperform	$64
May-08-24	Downgrade	BofA Securities	Buy → Neutral	$49 → $42
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$29 → $55
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy	$22 → $27
Jan-18-23	Resumed	Canaccord Genuity	Buy	$52
Aug-08-22	Upgrade	Goldman	Neutral → Buy	$28
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral	$8 → $20
Jun-17-22	Reiterated	Needham	Buy	$40 → $25
Mar-02-22	Resumed	Stifel	Buy	$23
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy	$15
Dec-08-21	Initiated	Wells Fargo	Overweight	$30
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$50 → $15
Sep-14-21	Resumed	Goldman	Neutral	$14
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral

Show Previous Ratings

Jun-25-25 08:00AM	Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025 (GlobeNewswire)
Jun-06-25 04:00PM	This IBD 50 Biotech's Got 'Rhythm' And Flashes 3 Telltale Clues (Investor's Business Daily)
Jun-05-25 08:06AM	This IBD 50 Biotech's Got 'Rhythm' - And Flashes 3 Telltale Clues (Investor's Business Daily)
May-29-25 12:50PM	Funds Go All In On Weight-Loss Leader; Stock Nears Highs (Investor's Business Daily)
May-14-25 08:00AM	Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program (GlobeNewswire)
03:10AM	Loading…
May-08-25 03:10AM	Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... (GuruFocus.com) -6.05%
May-07-25 03:22PM	Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment (Seeking Alpha)
03:21PM	Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
May-06-25 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-01-25 10:01AM	Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 10:01AM	Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-23-25 08:00AM	Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 (GlobeNewswire)
03:42PM	Loading…
Apr-08-25 03:42PM	Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily) +5.04%
01:38PM	Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (Seeking Alpha)
12:10PM	5 Stocks in Nasdaq ETF Fueling Index's Big Comeback Since 2008 (Zacks)
11:21AM	RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study (Zacks)
07:09AM	Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? (Zacks)
Apr-07-25 04:09PM	This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5% (GuruFocus.com) +17.06%
12:30PM	Rhythm seeks market expansion for Imcivree following Phase III victory (Clinical Trials Arena)
12:23PM	Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder (Benzinga)
07:51AM	Obesity drug data helps Rhythm defy market slide (BioPharma Dive)
07:00AM	Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity (GlobeNewswire)
Apr-06-25 12:00PM	Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity (GlobeNewswire)
Mar-20-25 04:55PM	Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
04:01PM	Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE (setmelanotide) in China with Termination of Agreement with RareStone Ltd. (GlobeNewswire)
Mar-19-25 04:23PM	Rhythm Pharmaceuticals gets Orphan Drug status for its hypothalamic obesity treatment in Japan (SeekingAlpha) +5.58%
04:01PM	Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan (GlobeNewswire)
07:00AM	Loading…
Mar-18-25 07:00AM	Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration (GlobeNewswire)
Feb-27-25 02:07AM	Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:38AM	Q4 2024 Rhythm Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 08:25AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily)
Feb-13-25 08:00AM	Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025 (GlobeNewswire)
Feb-05-25 08:00AM	Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February (GlobeNewswire)
Jan-28-25 09:55AM	Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet (Zacks)
Jan-22-25 08:50AM	Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Jan-10-25 07:15AM	Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones (GlobeNewswire)
Jan-02-25 10:15AM	Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential (TipRanks) +7.31%
Dec-20-24 02:24PM	Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential (Benzinga)
02:15PM	Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients as Young as 2 Years Old (GlobeNewswire)
Dec-06-24 06:48AM	Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities (TipRanks)
Dec-03-24 06:00AM	Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old (GlobeNewswire)
Nov-18-24 12:02PM	Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone (Investor's Business Daily)
07:00AM	Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide (GlobeNewswire)
Nov-13-24 06:30PM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology (GlobeNewswire) -6.23%
04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Nov-07-24 02:29AM	Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-24 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire) +11.38%
Nov-05-24 05:10PM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +6.15%
04:01PM	Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Nov-04-24 04:01PM	Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek 2024 (GlobeNewswire) +8.12%
Oct-29-24 10:01AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-24-24 06:00AM	Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome (GlobeNewswire)
Oct-23-24 08:00AM	Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024 (GlobeNewswire)
Oct-08-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Sep-21-24 02:23AM	Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish (Insider Monkey)
Sep-18-24 10:46AM	Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength? (Zacks)
Sep-16-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +7.37%
Sep-10-24 01:55PM	Biotech Stock Near Buy Point Amid Impressive Sales Track Record (Investor's Business Daily)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
Aug-26-24 08:02AM	Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE (setmelanotide) in Patients as Young as 2 years old (GlobeNewswire) +8.41%
08:00AM	Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September (GlobeNewswire)
Aug-13-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Aug-06-24 08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-31-24 09:10AM	Rhythm Pharmaceuticals Announces European Commission Expands IMCIVREE (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old (GlobeNewswire)
Jul-23-24 08:00AM	Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity (GlobeNewswire)
07:30AM	Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 (GlobeNewswire)
Jul-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +5.00% +7.34%
Jul-08-24 08:00AM	Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Jun-28-24 08:00AM	Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency (GlobeNewswire)
Jun-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +5.36%
Jun-03-24 04:02PM	Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 (GlobeNewswire) +6.08%
08:02AM	Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference (GlobeNewswire)
May-22-24 04:00AM	Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for IMCIVREE (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome (GlobeNewswire)
May-09-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
May-08-24 10:51AM	Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:06AM	Rhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ... (GuruFocus.com)
May-07-24 10:34PM	Q1 2024 Rhythm Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -10.32%
02:52PM	The 3 Best Nasdaq Stocks to Buy in May 2024 (InvestorPlace)
08:58AM	Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell (MT Newswires)
08:36AM	Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges (GuruFocus.com)
08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
May-06-24 08:00AM	Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting (GlobeNewswire)
Apr-30-24 10:01AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline (Zacks)
Apr-29-24 06:30PM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology (GlobeNewswire)
Apr-28-24 09:20AM	Jim Cramer Portfolio: 11 Latest Stocks to Buy (Insider Monkey)
Apr-24-24 04:01PM	Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (GlobeNewswire)
Apr-16-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Apr-01-24 08:00AM	Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing (GlobeNewswire)
Mar-25-24 08:00AM	Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist (GlobeNewswire)
Mar-22-24 07:01PM	Chief Technical Officer Joseph Shulman Sells 18,235 Shares of Rhythm Pharmaceuticals Inc (RYTM) (GuruFocus.com)
Mar-20-24 01:49AM	Insider Sell: Rhythm Pharmaceuticals Inc (RYTM) CEO David Meeker Disposes of 45,494 Shares (GuruFocus.com)
01:49AM	Insider Sell: Chief Technical Officer Joseph Shulman Sells 15,515 Shares of Rhythm ... (GuruFocus.com)
01:49AM	Insider Sell: CFO Hunter Smith Sells 15,515 Shares of Rhythm Pharmaceuticals Inc (RYTM) (GuruFocus.com)

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garfield Alastair	Chief Scientific Officer	Jul 02 '25	Sale	64.81	1,319	85,483	3,126	Jul 03 05:12 PM
German Christopher Paul	Corporate Controller & CAO	Jun 10 '25	Option Exercise	17.97	1,069	19,210	3,958	Jun 12 04:50 PM
German Christopher Paul	Corporate Controller & CAO	Jun 10 '25	Sale	67.19	2,069	139,016	1,889	Jun 12 04:50 PM
Cramer Pamela J.	Chief Human Resources Officer	Jun 06 '25	Option Exercise	6.80	7,031	47,811	26,240	Jun 10 04:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Jun 06 '25	Sale	68.05	7,031	478,435	19,209	Jun 10 04:45 PM
CHRISTOPHER PAUL GERMAN	Officer	Jun 10 '25	Proposed Sale	66.72	2,069	138,044		Jun 10 04:21 PM
PAMELA CRAMER	Officer	Jun 06 '25	Proposed Sale	66.18	7,031	465,312		Jun 06 04:25 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Option Exercise	4.59	65,431	300,328	68,431	Jun 05 04:16 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Sale	65.22	65,431	4,267,494	3,000	Jun 05 04:16 PM
Meeker David P	President and CEO	Jun 03 '25	Option Exercise	4.59	43,620	200,216	245,445	Jun 05 04:16 PM
Meeker David P	President and CEO	Jun 03 '25	Sale	65.05	43,620	2,837,333	201,825	Jun 05 04:16 PM
DAVID W MCGIRR	Director	Jun 03 '25	Proposed Sale	63.66	65,431	4,165,337		Jun 03 04:27 PM
DAVID MEEKER	Director	Jun 03 '25	Proposed Sale	63.66	43,621	2,776,913		Jun 03 04:27 PM
Smith Hunter C	Chief Financial Officer	May 30 '25	Option Exercise	6.88	23,400	160,992	133,329	Jun 03 04:15 PM
Smith Hunter C	Chief Financial Officer	May 30 '25	Sale	61.41	23,400	1,437,010	109,929	Jun 03 04:15 PM
HUNTER SMITH	Officer	May 30 '25	Proposed Sale	61.88	23,400	1,447,992		May 30 04:35 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 29 '25	Option Exercise	6.80	7,031	47,811	26,240	May 01 04:53 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 29 '25	Sale	65.09	7,031	457,663	19,209	May 01 04:53 PM
Mazabraud Yann	EVP, Head of International	Apr 29 '25	Sale	65.08	6,745	438,946	37,655	May 01 04:52 PM
YANN MAZZABRAUD	Officer	Apr 29 '25	Proposed Sale	64.41	6,745	434,445		Apr 29 04:21 PM
PAMELA CRAMER	Officer	Apr 29 '25	Proposed Sale	64.41	7,031	452,867		Apr 29 04:20 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 08 '25	Option Exercise	13.43	20,760	278,853	39,969	Apr 10 05:17 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 08 '25	Sale	60.14	20,760	1,248,490	19,209	Apr 10 05:17 PM
Mazabraud Yann	EVP, Head of International	Apr 08 '25	Sale	60.99	17,750	1,082,497	22,620	Apr 10 05:16 PM
PAMELA CRAMER	Officer	Apr 08 '25	Proposed Sale	54.96	20,760	1,140,970		Apr 08 04:18 PM
YANN MAZZABRAUD	Officer	Apr 08 '25	Proposed Sale	54.96	17,750	975,540		Apr 08 04:16 PM
German Christopher Paul	Corporate Controller & CAO	Mar 21 '25	Sale	54.23	344	18,655	2,889	Mar 24 05:47 PM
Mazabraud Yann	EVP, Head of International	Mar 14 '25	Option Exercise	22.28	75,000	1,671,000	115,370	Mar 18 09:16 PM
Mazabraud Yann	EVP, Head of International	Mar 14 '25	Sale	51.48	75,000	3,861,272	40,370	Mar 18 09:16 PM
YANN MAZZABRAUD	Officer	Mar 14 '25	Proposed Sale	50.24	75,000	3,768,000		Mar 14 04:21 PM
Smith Hunter C	Chief Financial Officer	Feb 19 '25	Sale	57.22	2,215	126,742	109,929	Feb 19 09:50 PM
Shulman Joseph	Chief Technical Officer	Feb 19 '25	Sale	57.22	1,228	70,266	8,509	Feb 19 09:49 PM
Meeker David P	President and CEO	Feb 19 '25	Sale	57.22	9,896	566,249	201,281	Feb 19 09:48 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 19 '25	Sale	57.22	2,035	116,443	5,858	Feb 19 09:46 PM
German Christopher Paul	Corporate Controller & CAO	Feb 19 '25	Sale	57.22	635	36,335	2,070	Feb 19 09:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 19 '25	Sale	57.22	982	56,190	19,209	Feb 19 09:43 PM
Smith Hunter C	Chief Financial Officer	Feb 12 '25	Sale	56.39	751	42,347	105,544	Feb 14 04:59 PM
Shulman Joseph	Chief Technical Officer	Feb 12 '25	Sale	56.40	469	26,452	5,612	Feb 14 04:57 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 12 '25	Sale	56.39	1,815	102,348	3,598	Feb 14 04:55 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 13 '25	Sale	58.00	1,205	69,890	2,393	Feb 14 04:55 PM
JENNIFER KAYDEN LEE	Officer	Feb 13 '25	Proposed Sale	57.64	1,205	69,456		Feb 13 04:31 PM
JENNIFER KAYDEN LEE	Officer	Feb 12 '25	Proposed Sale	57.58	1,205	69,384		Feb 12 04:42 PM
Shulman Joseph	Chief Technical Officer	Feb 11 '25	Sale	57.51	794	45,663	6	Feb 11 09:47 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 09 '25	Option Exercise	6.80	4,189	28,485	8,598	Feb 11 09:46 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 10 '25	Sale	58.91	4,189	246,783	4,409	Feb 11 09:46 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 11 '25	Sale	57.51	1,027	59,063	5,413	Feb 11 09:46 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 11 '25	Sale	57.51	701	40,315	16,891	Feb 11 09:45 PM
Smith Hunter C	Chief Financial Officer	Feb 11 '25	Sale	57.51	1,296	74,533	106,295	Feb 11 09:44 PM
JENNIFER KAYDEN LEE	Officer	Feb 10 '25	Proposed Sale	59.18	4,189	247,905		Feb 10 04:34 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 05 '25	Sale	60.55	3,066	185,640	972	Feb 07 05:05 PM
JENNIFER KAYDEN LEE	Officer	Feb 05 '25	Proposed Sale	59.95	3,066	183,807		Feb 05 04:20 PM
Smith Hunter C	Chief Financial Officer	Feb 04 '25	Sale	59.43	1,678	99,724	101,186	Feb 04 09:27 PM
Shulman Joseph	Chief Technical Officer	Feb 04 '25	Sale	59.43	1,281	76,130	2,657	Feb 04 09:26 PM
Meeker David P	President and CEO	Feb 04 '25	Sale	59.43	4,278	254,242	189,927	Feb 04 09:25 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 04 '25	Sale	59.43	1,447	85,995	4,038	Feb 04 09:23 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 04 '25	Sale	59.43	902	53,606	15,248	Feb 04 09:22 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 11 '24	Option Exercise	19.59	60,981	1,194,709	67,833	Nov 13 09:04 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 11 '24	Sale	66.33	66,861	4,434,882	972	Nov 13 09:04 PM
Shulman Joseph	Chief Technical Officer	Nov 11 '24	Option Exercise	12.63	13,281	167,760	13,281	Nov 13 09:02 PM
Shulman Joseph	Chief Technical Officer	Nov 11 '24	Sale	66.44	13,281	882,341	0	Nov 13 09:02 PM
JENNIFER KAYDEN LEE	Officer	Nov 11 '24	Proposed Sale	67.33	66,861	4,501,751		Nov 12 07:55 AM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '24	Option Exercise	19.02	4,688	89,166	18,188	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 06 '24	Option Exercise	19.02	4,687	89,147	18,187	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '24	Sale	65.00	4,688	304,720	13,500	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 06 '24	Sale	60.00	4,687	281,220	13,500	Nov 08 04:15 PM
PAMELA CRAMER	Officer	Nov 07 '24	Proposed Sale	62.65	4,688	293,703		Nov 07 04:36 PM
PAMELA CRAMER	Officer	Nov 06 '24	Proposed Sale	56.25	4,687	263,644		Nov 06 05:07 PM
GOOD JENNIFER L	Director	Sep 17 '24	Option Exercise	21.54	31,751	684,066	34,751	Sep 19 04:30 PM
GOOD JENNIFER L	Director	Sep 17 '24	Sale	52.40	31,751	1,663,803	3,000	Sep 19 04:30 PM
JENNIFER GOOD	Director	Sep 17 '24	Proposed Sale	49.52	31,751	1,572,310		Sep 17 04:42 PM
Cramer Pamela J.	Chief Human Resources Officer	Sep 09 '24	Option Exercise	19.02	4,099	77,963	17,599	Sep 11 04:32 PM
Cramer Pamela J.	Chief Human Resources Officer	Sep 09 '24	Sale	50.03	4,099	205,062	13,500	Sep 11 04:32 PM
TETRAULT LYNN A.	Director	Sep 10 '24	Option Exercise	10.51	17,501	183,944	20,501	Sep 11 04:31 PM
TETRAULT LYNN A.	Director	Sep 09 '24	Option Exercise	18.99	3,199	60,749	6,199	Sep 11 04:31 PM
TETRAULT LYNN A.	Director	Sep 10 '24	Sale	49.65	17,501	868,923	3,000	Sep 11 04:31 PM
TETRAULT LYNN A.	Director	Sep 09 '24	Sale	50.04	3,199	160,068	3,000	Sep 11 04:31 PM
GOOD JENNIFER L	Director	Sep 09 '24	Option Exercise	13.34	37,241	496,706	40,241	Sep 11 04:30 PM
GOOD JENNIFER L	Director	Sep 09 '24	Sale	50.45	37,241	1,878,700	3,000	Sep 11 04:30 PM
LYNN TETRAULT393 COMMONWEALTH	Director	Sep 10 '24	Proposed Sale	50.66	17,501	886,601		Sep 10 04:22 PM
JENNIFER GOOD	Director	Sep 09 '24	Proposed Sale	49.25	16,749	824,888		Sep 09 04:31 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 26 '24	Option Exercise	19.02	3,200	60,864	16,700	Aug 28 04:31 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 26 '24	Sale	50.01	3,200	160,018	13,500	Aug 28 04:31 PM
TETRAULT LYNN A.	Director	Aug 26 '24	Option Exercise	18.99	4,300	81,657	7,300	Aug 28 04:31 PM
TETRAULT LYNN A.	Director	Aug 26 '24	Sale	50.01	4,300	215,029	3,000	Aug 28 04:31 PM
GOOD JENNIFER L	Director	Aug 26 '24	Option Exercise	18.63	14,508	270,322	17,508	Aug 28 04:30 PM
GOOD JENNIFER L	Director	Aug 26 '24	Sale	50.01	14,508	725,526	3,000	Aug 28 04:30 PM
JENNIFER GOOD	Director	Aug 26 '24	Proposed Sale	46.12	35,000	1,614,200		Aug 26 04:27 PM
LYNN TETRAULT393 COMMONWEALTH	Director	Aug 26 '24	Proposed Sale	46.12	7,499	345,854		Aug 26 04:27 PM
PAMELA CRAMER	Officer	Aug 26 '24	Proposed Sale	46.12	7,299	336,630		Aug 26 04:26 PM
TETRAULT LYNN A.	Director	Aug 12 '24	Option Exercise	4.15	10,000	41,500	13,000	Aug 14 04:15 PM
TETRAULT LYNN A.	Director	Aug 12 '24	Sale	44.65	10,000	446,462	3,000	Aug 14 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 09 '24	Option Exercise	19.02	30,771	585,264	62,506	Aug 13 04:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 09 '24	Sale	45.15	49,006	2,212,498	13,500	Aug 13 04:45 PM
LYNN TETRAULT393 COMMONWEALTH	Director	Aug 12 '24	Proposed Sale	45.26	10,000	452,600		Aug 12 04:13 PM
PAMELA CRAMER	Officer	Aug 09 '24	Proposed Sale	45.87	49,006	2,247,905		Aug 09 04:09 PM
Cramer Pamela J.	Chief Human Resources Officer	Jul 29 '24	Sale	49.06	1,395	68,439	31,735	Jul 30 05:09 PM
Shulman Joseph	Chief Technical Officer	Jul 16 '24	Option Exercise	27.35	10,468	286,300	10,498	Jul 18 05:59 PM
Shulman Joseph	Chief Technical Officer	Jul 16 '24	Sale	53.00	10,468	554,817	30	Jul 18 05:59 PM
Shulman Joseph	Chief Technical Officer	Jul 12 '24	Option Exercise	21.38	5,313	113,592	5,343	Jul 16 04:30 PM
Shulman Joseph	Chief Technical Officer	Jul 12 '24	Sale	50.01	5,313	265,725	30	Jul 16 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RYTM

Rhythm Pharmaceuticals Inc

Upgrade your FINVIZ experience